Integrative Systems Biology Investigation of Fabry Disease
AbstractFabry disease (FD) is a rare X-linked recessive genetic disorder caused by a deficient activity of the lysosomal enzyme alpha-galactosidase A (GLA) and is characterised by intra-lysosomal accumulation of globotriaosylceramide (Gb3). We performed a meta-analysis of peer-reviewed publications including high-throughput omics technologies including naïve patients and those undergoing enzyme replacement therapy (ERT). This study describes FD on a systems level using a systems biology approach, in which molecular data sourced from multi-omics studies is extracted from the literature and integrated as a whole in order to reveal the biochemical processes and molecular pathways potentially affected by the dysregulation of differentially expressed molecules. In this way new insights are provided that describe the pathophysiology of this rare disease. Using gene ontology and pathway term clustering, FD displays the involvement of major biological processes such as the acute inflammatory response, regulation of wound healing, extracellular matrix (ECM) remodelling, regulation of peptidase activity, and cellular response to reactive oxygen species (ROS). Differential expression of acute-phase response proteins in the groups of naïve (up-regulation of ORM1, ORM2, ITIH4, SERPINA3 and FGA) and ERT (down-regulation of FGA, ORM1 and ORM2) patients could be potential hallmarks for distinction of these two patient groups. View Full-Text
- Supplementary File 1:
Supplementary (PDF, 917 KB)
Share & Cite This Article
Fernandes, M.; Husi, H. Integrative Systems Biology Investigation of Fabry Disease. Diseases 2016, 4, 35.
Fernandes M, Husi H. Integrative Systems Biology Investigation of Fabry Disease. Diseases. 2016; 4(4):35.Chicago/Turabian Style
Fernandes, Marco; Husi, Holger. 2016. "Integrative Systems Biology Investigation of Fabry Disease." Diseases 4, no. 4: 35.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.